Exiqon's Q3 Revenues Down 1 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Exiqon today reported that its third quarter revenues declined around 1 percent year over year.

The Danish firm reported total revenues of DKK 29.8 million ($5.5 million) for the quarter, compared to DKK 30.1 million for Q3 2012. It said that its research product sales and services, excluding OEM, increased 17 percent year over year to DKK 26.5 million, with North American sales for those products up 44 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.